Astrocytic ablation of truncated TrkB receptors reduces amyloid plaques and prevents synaptic loss in 5xFAD mice
Brain-derived neurotrophic factor (BDNF) is essential for nervous system development and function and exerts its effects primarily through the tropomyosin receptor kinase B (TrkB). The Ntrk2 gene encodes a full-length receptor (TrkB.FL) and two truncated isoforms (TrkB.T1 and TrkB.T2, collectively TrkB.T) that lack the intracellular tyrosine kinase domain. TrkB.T is expressed predominantly in astrocytes and is thought to inhibit BDNF-TrkB.FL signaling by sequestering BDNF and forming signaling-deficient heterodimers with TrkB.FL. Here, we investigated whether selective ablation of astrocytic TrkB.T could ameliorate Alzheimer's disease (AD) pathology by enhancing endogenous BDNF-TrkB.FL signaling. Astrocyte-specific deletion of the Ntrk2 gene at 5 weeks of age reduced cortical TrkB.T expression by more than 80% without affecting TrkB.FL levels. TrkB.T ablation increased the size of Bassoon-positive presynaptic active zones, consistent with enhanced BDNF-TrkB.FL signaling. Remarkably, astrocytic TrkB.T ablation reduced {beta}-amyloid plaque burden by more than 60% in the cortex, hippocampus, and subiculum of 6-month-old 5xFAD mice, despite having no detectable effect on microgliosis or astrogliosis. Furthermore, TrkB.T ablation prevented reductions in the density and size of PSD-95-positive postsynaptic sites in the cortex and hippocampus of 5xFAD mice at 1 year old. Together, these findings identify astrocytic TrkB.T as an important regulator of amyloid pathology and synaptic integrity in an AD mouse model. Our results suggest that selectively reducing TrkB.T expression represents a promising therapeutic strategy to enhance endogenous neuroprotective BDNF-TrkB.FL signaling, reduce amyloid pathology, and preserve synaptic integrity in AD.